
    
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel-cohort,
      dose-ranging study of participants with mild to moderate plaque psoriasis. This Phase 2 study
      has been designed to investigate the clinical safety and efficacy of EDP1815 and to identify
      an optimal dose in subjects with mild to moderate psoriasis.
    
  